Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell(Instituto Oncológico Dr. Rosell), Ana Drozdowskyj(Pivotal (Spain)), P. Bombaron(Centre Hospitalier de Mulhouse), Vittorio Gebbia(Università degli Studi di Enna Kore), Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), Josefa Terrasa(Hospital Universitario Son Dureta), Amelia Insa(Hospital Clínico Universitario de Valencia), Michèle Milella(National Cancer Institute), Alessandra Bearz(Centro di Riferimento Oncologico), Manuel Cobo(Instituto de Investigación Biomédica de Málaga), Flavia Longo(Policlinico Umberto I), Guillermo López-Vivanco(Hospital de Cruces), Ramón Palmero(Institut Català d'Oncologia), R. Corre(Hôpital Pontchaillou), Rosario García‐Campelo, Pilar Garrido(Hospital Universitario Ramón y Cajal), Julien Mazières(Université Toulouse III - Paul Sabatier), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), José Muñoz-Langa(Hospital Universitario Doctor Peset), Lioba Ferrera-Delgado, Isabel Bover(Hospital Universitari Sant Joan de Reus), Reyes Bernabé(Hospital Universitario de Valme), Miguel Ángel Moreno(Complejo Hospitalario de Jaén), Nathalie Baize(Centre Hospitalier Universitaire d'Angers), A. Vergnenègre(Hôpital Dupuytren), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Á. Artal(Hospital Universitario Miguel Servet), Olivier Molinier(Centre Hospitalier du Mans), Dolores Isla(Hospital Clínico Universitario Lozano Blesa), Manuel Dómine(Chinese Academy of Medical Sciences & Peking Union Medical College), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda), Giuseppe Altavilla(Azienda Ospedaliera Universitaria Policlinico "G. Martino"), Noemı́ Reguart(Hospital Clínic de Barcelona), Enriqueta Felip(Institut Català d'Ornitologia), Enric Carcereny(Institut Català d'Ornitologia), Enrico Cortesi(Sapienza University of Rome), José Miguel Sánchez(Research Institute Hospital 12 de Octubre), Javier Valdivia(Hospital Universitario Virgen de las Nieves), Radj Gervais(Centre François Baclesse), Rut Porta(Catalan Institute for Water Research), Ramón García-Gómez(Hospital General Universitario Gregorio Marañón), Alfonso Illiano, Éric Dansin(Centre Oscar Lambret), G. Robinet(Centre Hospitalier Régional Universitaire de Brest), Cinta Pallarés(Hospital de Sant Pau), Teresa Morán(Institute of Agrifood Research and Technology), Ulpiano Jiménez(Hospital Universitario de La Princesa), María Sanchez-Ronco(Universidad de Alcalá), Filippo de Marinis(Carlo Forlanini Hospital)
Cited by 5,524
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k